Sodium-glucose cotransporter 2 (SGLT2) inhibitor initiation and hepatocellular carcinoma prognosis.
Sodium-glucose cotransporter 2 (SGLT2) inhibitor initiation and hepatocellular carcinoma prognosis.
复制标题
钠-葡萄糖协同转运蛋白 2 (SGLT2) 抑制剂启动与肝细胞癌预后。
DOI：
10.1371/journal.pone.0274519
复制
发表时间：
2022
期刊：
影响因子：
3.7
通讯作者：
中科院分区：
文献类型：
--
作者：
钠-葡萄糖协同转运蛋白2（SGLT 2）抑制剂是一类相对较新的抗糖尿病药物。实验室研究的新发现表明，SGLT 2抑制剂可以改善肝功能并抑制肝细胞癌（HCC）细胞的增殖。本研究的目的是检验SGLT 2抑制剂治疗可改善人群HCC预后的假设。我们使用美国国家监测、流行病学和最终结果（SEER）-医疗保险相关数据来评价SGLT 2抑制剂启动对HCC患者生存期的作用。纳入了2014年至2017年期间新诊断的3，185名66岁或以上的HCC患者，这些患者患有既存2型糖尿病，并随访至2019年底。从Medicare Part D文件中提取SGLT 2抑制剂启动相关信息。调整潜在混杂因素后，SGLT 2抑制剂治疗开始与死亡风险显著降低相关（HR = 0. 68，95% CI = 0. 54 - 0. 86），与使用时间较长相关性更强（HR = 0. 60，95% CI = 0. 41 - 0. 88）。此外，我们发现，无论患者人口统计学变量、肿瘤特征和癌症治疗如何，SGLT 2抑制剂启动与14%至60%的较低死亡风险相关。我们的大型SEER-Medicare关联数据研究表明，与未使用SGLT 2抑制剂相比，开始使用SGLT 2抑制剂与既存2型糖尿病的HCC患者的总生存期改善相关。需要进一步的研究来证实我们的发现并阐明这种关联背后的可能机制。
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a relatively new class of antidiabetic drugs. Emerging findings from laboratory studies indicate that SGLT2 inhibitors can improve liver function and suppress the proliferation of hepatocellular carcinoma (HCC) cells. The aim of this study was to test the hypothesis that initiation of SGLT2 inhibitors improves HCC prognosis in a human population. We used National Surveillance, Epidemiology and End Results (SEER)—Medicare linked data in the United States to evaluate the role of SGLT2 inhibitor initiation on the survival of HCC patients. 3,185 HCC patients newly diagnosed between 2014 and 2017 aged 66 years or older with pre-existing type 2 diabetes were included and followed to the end of 2019. Information on SGLT2 inhibitor initiation was extracted from the Medicare Part D file. SGLT2 inhibitor initiation was associated with significantly lower mortality risk after adjusting for potential confounders (HR = 0.68, 95% CI = 0.54–0.86) with stronger association for longer duration of use (HR = 0.60, 95% CI = 0.41–0.88). Further, we found that SGLT2 inhibitor initiation was associated with a lower risk mortality risk ranging from 14% to 60% regardless of patient demographic variables, tumor characteristics, and cancer treatments. Our large SEER-Medicare linked data study indicates that SGLT2 inhibitor initiation was associated with improved overall survival of HCC patients with pre-existing type 2 diabetes compared with no SGLT2 inhibitor use. Further studies are needed to confirm our findings and elucidate the possible mechanisms behind the association.
登录
查看更多内容
影响因子：
5.6
作者：
Li L;Li Q;Huang W;Han Y;Tan H;An M;Xiang Q;Zhou R;Yang L;Cheng Y
通讯作者：
Cheng Y
DOI：
10.2147/dmso.s154602
发表时间：
2018
期刊：
Diabetes, metabolic syndrome and obesity : targets and therapy
影响因子：
--
作者：
Cavaiola TS;Pettus J
通讯作者：
Pettus J
影响因子：
5.1
作者：
Brar G;Greten TF;Graubard BI;McNeel TS;Petrick JL;McGlynn KA;Altekruse SF
通讯作者：
Altekruse SF
影响因子：
16.2
作者：
Daniele, Giuseppe;Xiong, Juan;Abdul-Ghani, Muhammad
通讯作者：
Abdul-Ghani, Muhammad
影响因子：
25.7
作者：
Dyson, Jessica;Jaques, Bryan;Reeves, Helen L.
通讯作者：
Reeves, Helen L.